Omadacycline versus Moxifloxacin for the Treatment of Community-Acquired Pneumonia: A Real-World Retrospective Comparative Study of Efficacy and Safety

To compare the real-world clinical effectiveness and safety of omadacycline versus moxifloxacin in treating adult patients with CAP.This single-center retrospective cohort study was conducted at the First Affiliated Hospital of Guangxi University of Science and Technology. A total of 348 adult inpatients diagnosed with CAP between June 2022 and December 2024 were enrolled and categorized into the Omadacycline group (n=170) and the Moxifloxacin group (n=178). The primary efficacy endpoint was early clinical response (ECR) assessed 72-120 hours after treatment initiation. Secondary endpoints included overall clinical response rate, bacterial eradication rate, changes in inflammatory biomarkers (WBC, CRP, PCT), and safety outcomes (adverse event incidence).